JY
TBPH icon

Jeff Yass’s Theravance Biopharma TBPH Stock Holding History

Jeff Yass’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
14,300
+2,000
+16% +$33.1K ﹤0.01% 11531
2026
Q1 		$200K Sell
12,300
-67,000
-84% -$1.19M ﹤0.01% 11712
2025
Q4 		$1.48M Buy
79,300
+65,000
+455% +$1.08M ﹤0.01% 6285
2025
Q3 		$209K Buy
+14,300
New +$181K ﹤0.01% 10903
2024
Q1 		– Sell
-66,000
Closed -$742K – 13303
2023
Q4 		$742K Sell
66,000
-19,600
-23% -$197K ﹤0.01% 7721
2023
Q3 		$739K Buy
85,600
+69,100
+419% +$667K ﹤0.01% 7321
2023
Q2 		$171K Sell
16,500
-115,200
-87% -$1.27M ﹤0.01% 10440
2023
Q1 		$1.43M Sell
131,700
-92,000
-41% -$973K ﹤0.01% 5915
2022
Q4 		$2.51M Buy
223,700
+124,700
+126% +$1.31M ﹤0.01% 4314
2022
Q3 		$1M Buy
99,000
+10,900
+12% +$102K ﹤0.01% 6627
2022
Q2 		$798K Buy
88,100
+24,000
+37% +$221K ﹤0.01% 7077
2022
Q1 		$613K Buy
64,100
+51,900
+425% +$509K ﹤0.01% 8425
2021
Q4 		$135K Sell
12,200
-192,200
-94% -$1.68M ﹤0.01% 11909
2021
Q3 		$1.51M Buy
204,400
+152,000
+290% +$1.7M ﹤0.01% 6454
2021
Q2 		$761K Buy
52,400
+9,800
+23% +$184K ﹤0.01% 8522
2021
Q1 		$869K Buy
+42,600
New +$810K ﹤0.01% 8094
2020
Q4 		– Sell
-26,400
Closed -$390K – 11719
2020
Q3 		$390K Buy
+26,400
New +$495K ﹤0.01% 8196
2020
Q2 		– Sell
-40,700
Closed -$941K – 10908
2020
Q1 		$941K Buy
+40,700
New +$1.02M ﹤0.01% 5550
2019
Q3 		– Sell
-21,100
Closed -$345K – 10834
2019
Q2 		$345K Buy
21,100
+11,400
+118% +$231K ﹤0.01% 8047
2019
Q1 		$220K Buy
9,700
+200
+2% +$5.07K ﹤0.01% 7740
2018
Q4 		$243K Sell
9,500
-2,000
-17% -$54K ﹤0.01% 7394
2018
Q3 		$376K Buy
+11,500
New +$313K ﹤0.01% 7037
2017
Q2 		– Sell
-19,700
Closed -$725K – 9824
2017
Q1 		$725K Sell
19,700
-11,500
-37% -$367K ﹤0.01% 5796
2016
Q4 		$995K Buy
+31,200
New +$968K ﹤0.01% 5550

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jeff Yass's TBPH Position: Q2 2026 in Review

Jeff Yass reduced its Theravance Biopharma (TBPH) stake by 83% in Q2 2026, selling an estimated $4.7M and leaving 57,524 shares worth $978K. The position accounts for ﹤0.01% of the portfolio, ranked #8255.

Jeff Yass first reported a position in TBPH in Q2 2014 and has held it in 33 quarters since. The position peaked at $5.54M in Q1 2026. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Jeff Yass held 57,524 shares of Theravance Biopharma worth $978K as of Q2 2026.
  • Jeff Yass sold 284,055 Theravance Biopharma shares in Q2 2026, an estimated $4.7M.
  • Theravance Biopharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8255 holding.
  • Jeff Yass first reported a position in Theravance Biopharma in Q2 2014 and has held it in 33 quarters since.
  • Jeff Yass's Theravance Biopharma position peaked at $5.54M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.